Literature DB >> 23709361

Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?

Changsu Han1, Chi-Un Pae.   

Abstract

Asian and western countries differ in the prevalence, symptom manifestation, diagnostic procedures, patient recognition and treatments of major depressive disorder (MDD), according to a number of studies. Ethnic differences in pharmacological profiles are also important in the prescription of certain antipsychotic medications because they may impact treatment outcomes and adverse events. Differential pharmacokinetic and pharmacodynamic properties of antipsychotics may be practically useful in the control of specific depressive symptoms. Furthermore, patient compliance with prescribed medications has been found to be different across races and ethnicities. Therefore, this article explores practical clinical issues for the use of atypical antipsychotics in patients with MDD, focusing on ethno-cultural differences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23709361     DOI: 10.1007/s40263-012-0033-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  35 in total

1.  Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.

Authors:  Dan J Stein; Borwin Bandelow; Charles Merideth; Bengt Olausson; Johan Szamosi; Hans Eriksson
Journal:  Hum Psychopharmacol       Date:  2011-12-06       Impact factor: 1.672

2.  Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations.

Authors:  Kensuke Utsunomiya; Takahiro Shinkai; Shinichi Sakata; Kenji Yamada; Hsin-I Chen; Vincenzo De Luca; Rudi Hwang; Osamu Ohmori; Jun Nakamura
Journal:  Neurosci Lett       Date:  2011-12-06       Impact factor: 3.046

3.  Cross-national epidemiology of major depression and bipolar disorder.

Authors:  M M Weissman; R C Bland; G J Canino; C Faravelli; S Greenwald; H G Hwu; P R Joyce; E G Karam; C K Lee; J Lellouch; J P Lépine; S C Newman; M Rubio-Stipec; J E Wells; P J Wickramaratne; H Wittchen; E K Yeh
Journal:  JAMA       Date:  1996 Jul 24-31       Impact factor: 56.272

4.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

5.  Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.

Authors:  Reiji Yoshimura; Taro Kishi; Hikaru Hori; Atsuko Ikenouchi-Sugita; Asuka Katsuki; Wakako Umene-Nakano; Nakao Iwata; Jun Nakamura
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-07-17       Impact factor: 5.067

6.  Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Authors:  Chien-Ho Lin; Shih-Hsien Lin; Fong-Lin Jang
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

7.  Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong.

Authors:  H Chiu; P Shum; J Lau; L Lam; S Lee
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

8.  Aripiprazole as an adjunctive treatment for refractory unipolar depression.

Authors:  David J Hellerstein; Sarai Batchelder; Steven Hyler; Bachaar Arnaout; Virginia Corpuz; Lisa Coram; Gony Weiss
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-12-03       Impact factor: 5.067

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Depression among Asian Americans: Review and Recommendations.

Authors:  Zornitsa Kalibatseva; Frederick T L Leong
Journal:  Depress Res Treat       Date:  2011-09-27
View more
  5 in total

1.  Antipsychotic Medications in Major Depression and the Association with Treatment Satisfaction and Quality of Life: Findings of Three National Surveys on Use of Psychotropics in China Between 2002 and 2012.

Authors:  Yu-Xi Wang; Yu-Tao Xiang; Yun-Ai Su; Qian Li; Liang Shu; Chee H Ng; Gabor S Ungvari; Helen Fk Chiu; Yu-Ping Nin; Gao-Hua Wang; Pei-Shen Bai; Tao Li; Li-Zhong Sun; Jian-Guo Shi; Xian-Sheng Chen; Qi-Yi Mei; Ke-Qing Li; Xin Yu; Tian-Mei Si
Journal:  Chin Med J (Engl)       Date:  2015-07-20       Impact factor: 2.628

2.  Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.

Authors:  Hong Jin Jeon; Po-Chung Ju; Ahmad Hatim Sulaiman; Salina Abdul Aziz; Jong-Woo Paik; Wilson Tan; Daisy Bai; Cheng-Ta Li
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

3.  Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.

Authors:  Gang Wang; Le Xiao; Hongye Ren; Kenneth Simonsen; Jingdong Ma; Xiangdong Xu; Ping Guo; Zhiren Wang; Ludong Bai; Elin Heldbo Reines; Lene Hammer-Helmich
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-30       Impact factor: 2.989

4.  Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders.

Authors:  Kuan-Pin Su; Yutaka Matsuoka; Chi-Un Pae
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

5.  Factors associated with antipsychotic use in non-psychotic depressed patients: results from a clinical multicenter survey.

Authors:  Jingjing Zhou; Tong Zhu; Xuequan Zhu; Britta Galling; Le Xiao
Journal:  BMC Psychiatry       Date:  2022-02-03       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.